
CVE:QIPT
This summary was created by AI, based on 1 opinions in the last 12 months.
Quipt Home Medical (QIPT-X) has an interesting profile as it navigates a transitioning market post-COVID. Past ownership of the stock suggests that it has faced challenges, particularly with investor interest dwindling in recent years. The medical supply space, once bustling due to the pandemic, has cooled down, leading to a hesitant investment climate around companies like QIPT. Nonetheless, there are considerations of acquisition on the horizon, fostering some optimism that it may attract a buyer soon. This potential for a buyout could provide a lifeline, and investors might benefit if the market sentiment shifts positively.
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Revenues have grown 41% since 2020 at $102M for 2021. 10% organic growth. Operational metrics are impressive that sets up the company well for future recurring revenues. Still some runway left, trading at 22x earnings. The balance sheet is healthy with net cash. Unlock Premium - Try 5i Free